Antibe Therapeutics Past Earnings Performance
Past criteria checks 0/6
Antibe Therapeuticshan disminuido a un ritmo medio anual de -10.5%, mientras que en la industria Pharmaceuticals los ingresos han sido de growing a 27.3% anuales. Los ingresos han sido declining a una tasa media anual de 66%.
Key information
-6.8%
Earnings growth rate
12.3%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | -71.3% |
Return on equity | -70.3% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?
Dec 15We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully
Mar 20Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business
Oct 16Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook
Feb 11We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate
Jan 07Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)
Jul 31Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021
Jul 29Revenue & Expenses BreakdownBeta
How Antibe Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -18 | 9 | 11 |
30 Sep 23 | 0 | -18 | 9 | 11 |
30 Jun 23 | 0 | -19 | 9 | 12 |
31 Mar 23 | 0 | -19 | 8 | 12 |
31 Dec 22 | 0 | -21 | 8 | 14 |
30 Sep 22 | 0 | -22 | 8 | 15 |
30 Jun 22 | 0 | -24 | 8 | 16 |
31 Mar 22 | 0 | -25 | 9 | 16 |
31 Dec 21 | 0 | -26 | 9 | 16 |
30 Sep 21 | 0 | -26 | 9 | 17 |
30 Jun 21 | -1 | -25 | 9 | 16 |
31 Mar 21 | 0 | -24 | 9 | 15 |
31 Dec 20 | 2 | -25 | 10 | 14 |
30 Sep 20 | 5 | -23 | 11 | 12 |
30 Jun 20 | 8 | -21 | 11 | 10 |
31 Mar 20 | 10 | -19 | 12 | 9 |
31 Dec 19 | 10 | -17 | 12 | 7 |
30 Sep 19 | 10 | -16 | 12 | 7 |
30 Jun 19 | 10 | -13 | 11 | 5 |
31 Mar 19 | 10 | -13 | 11 | 5 |
31 Dec 18 | 9 | -11 | 9 | 4 |
30 Sep 18 | 9 | -9 | 8 | 4 |
30 Jun 18 | 9 | -8 | 7 | 3 |
31 Mar 18 | 9 | -7 | 7 | 3 |
31 Dec 17 | 9 | -7 | 8 | 2 |
30 Sep 17 | 8 | -7 | 8 | 2 |
30 Jun 17 | 9 | -6 | 8 | 2 |
31 Mar 17 | 9 | -6 | 8 | 1 |
31 Dec 16 | 9 | -5 | 7 | 1 |
30 Sep 16 | 9 | -4 | 7 | 1 |
30 Jun 16 | 7 | -4 | 6 | 1 |
31 Mar 16 | 4 | -3 | 4 | 1 |
31 Dec 15 | 2 | -3 | 3 | 1 |
30 Sep 15 | 0 | -3 | 2 | 1 |
30 Jun 15 | 0 | -3 | 2 | 1 |
31 Mar 15 | 0 | -4 | 2 | 2 |
31 Dec 14 | 0 | -5 | 2 | 2 |
30 Sep 14 | 0 | -5 | 2 | 3 |
30 Jun 14 | 0 | -4 | 2 | 2 |
31 Mar 14 | 0 | -3 | 1 | 1 |
31 Dec 13 | 0 | -2 | 1 | 1 |
30 Sep 13 | 0 | -1 | 1 | 0 |
Beneficios de calidad: ATE actualmente no es rentable.
Creciente margen de beneficios: ATE actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: ATE no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 10.5% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ATE en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: ATE no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (109.7%).
Return on Equity
Alto ROE: ATE tiene un Rendimiento de los fondos propios negativo (-61.38%), ya que actualmente no es rentable.